Compare Nuwellis Inc (NUWE) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Oklo Inc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Oklo Inc trades at $35.09 (market cap $6.43B). The key difference: Oklo Inc is far larger — about 2922.7× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 16,238,368). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Oklo Inc for 31 Days on average.
| NUWE | OKLO | |
|---|---|---|
Market Cap | $2.20M | $6.43B |
Volume | 121,544 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $146.65 | $174.14 |
52-Week Low | $0.68 | $34.57 |
Typical Hold Time | 26 Days | 31 Days |
Enterprise Value | -$1.52M | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
OKLO trades at $36.82, down 4.49% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Recent earnings have missed expectations in two of the last three quarters. However, analyst sentiment remains strong with 71% buy ratings and a $78.63 consensus price target, reflecting optimism about the nuclear energy opportunity.
The outlook balances high growth potential in the nuclear sector against significant execution risks. While the $10 trillion nuclear opportunity and partnerships with hyperscalers provide upside, OKLO faces challenges including negative cash flow from operations, substantial dilution from recent stock sales, and intense competition in the small modular reactor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
